Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The primary goal of the collaboration is joint research into trending and next-generation molecules
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Subscribe To Our Newsletter & Stay Updated
